Glioblastoma has a gigantic unmet medical need. Molecular knowledge has evolved substantially, including data on clonal selection with progression. Past trials for all-comers may have produced false negative results. Molecular precision at progression needs workup of new tissue and revisiting drugs with focus on brain tumor penetration may yield surprises.
http://ift.tt/2iRpvTE
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου